An in silico approach to study the interaction of BHA with selected steroid hormone receptors and investigating it's agonistic and antagonistic properties.
Agonists
Antagonists
Antioxidant
BHA
Molecular docking
Journal
In silico pharmacology
ISSN: 2193-9616
Titre abrégé: In Silico Pharmacol
Pays: Germany
ID NLM: 101623954
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
06
2020
accepted:
18
12
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
Antioxidant food additives were routinely used for increasing the keeping quality of packaged food items. Butylated Hydroxyanisole (BHA) is one of the most widely used synthetic phenolic antioxidants of such kind. Although quantity of antioxidants in packaged eatables and admissible daily intake (ADI) per person per day are limited by laws, the urbanisation and changes in lifestyle has cross these limits. Although studies on BHA has been carried out, there exists a great deal of uncertainty about the exact molecular mechanism of interaction of BHA with various receptors in the body. Since earlier reports suggested BHA plausibly interferes with reproductive system development, we opted docking of critical receptors of endogenous hormones controlling growth and development of reproductive system with BHA. Nuclear receptors of estrogen (ER), androgen (AR) and progesterone (PR) were selected for this purpose. This manuscript describes the comparison of binding pattern of BHA towards AR, ER and PR along with their agonists and antagonist. Lamarckian Genetic Algorithm of AutoDock 4.0 was used for analysing the mode of binding of ligands with the receptors. It is evident form the docking studies that, BHA exhibited similar binding pattern` with antagonists of AR and agonists of ER. But the interaction of BHA with PR was not compatible with either agonists or antagonists. The docking patterns produced could reliably demonstrate the interactions of BHA with selected receptors and also predict its possible agonistic and antagonistic action.
Identifiants
pubmed: 33520595
doi: 10.1007/s40203-020-00070-x
pii: 70
pmc: PMC7843719
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Informations de copyright
© The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interests.
Références
J Cell Mol Med. 2013 Jan;17(1):1-11
pubmed: 23279634
Toxicol Appl Pharmacol. 2014 Aug 1;278(3):201-8
pubmed: 24055644
SAR QSAR Environ Res. 2010 Apr;21(3-4):351-67
pubmed: 20544555
J Appl Toxicol. 2018 Jul;38(7):944-957
pubmed: 29460325
Mol Cell Endocrinol. 2012 Jan 30;348(2):418-29
pubmed: 21803119
Reprod Biol Endocrinol. 2019 Jan 13;17(1):5
pubmed: 30636624
Cancer Lett. 1995 Jun 29;93(1):49-54
pubmed: 7600543
Toxicol Mech Methods. 2016 Sep;26(7):511-519
pubmed: 27388148
Endocr Rev. 2009 Jun;30(4):293-342
pubmed: 19502515
Toxicol Sci. 2000 Feb;53(2):278-88
pubmed: 10696776
Sci Rep. 2016 Feb 22;6:21285
pubmed: 26899418
Chem Biol Interact. 2019 Apr 25;303:90-97
pubmed: 30826252
J Clin Oncol. 2002 Jul 1;20(13):3001-15
pubmed: 12089231
Environ Health Perspect. 1995 Jun;103(6):582-7
pubmed: 7556011
Bioorg Med Chem. 2006 Nov 1;14(21):7160-74
pubmed: 16876421
Toxicology. 2005 Mar 1;208(1):49-62
pubmed: 15664432
J Comput Aided Mol Des. 2000 Aug;14(6):559-72
pubmed: 10921772
Toxicology. 2005 Sep 15;213(1-2):147-56
pubmed: 16023279
Toxicol In Vitro. 2016 Apr;32:269-77
pubmed: 26812027
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:264-72
pubmed: 25597633
Regul Toxicol Pharmacol. 2007 Feb;47(1):68-77
pubmed: 16996185